HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
In This Section
Bhavya Doshi, MD
Attending Physician
Dr. Doshi is a pediatric hematologist who specializes in bleeding and clotting disorders. Her research focuses on hemophilia, alloantibody responses, and improving diagnostics for patients with bleeding disorders.
Bio
Dr. Doshi is a pediatric hematologist with a focus on children with bleeding and clotting disorders. Her research spans from bench to bedside and focuses on hemophilia and other bleeding disorders, alloantibody responses, and improving diagnostics for patients with bleeding disorders. Her basic science laboratory studies the mechanisms of immune responses to protein-based replacement therapies with the goal to translate these findings to novel therapies.
Education and Training
BS, Emory University College of Arts & Sciences (Biology), 2004
MD, Emory University School of Medicine, 2008
Residency, Emory University School of Medicine (Pediatrics), 2012-2015
Fellowship, Children's Hospital of Philadelphia (Hematology/Oncology), 2015-2018
Titles and Academic Titles
Attending Physician
Assistant Professor of Pediatrics
Professional Memberships
Alpha Omega Alpha, 2011-
Hemostasis and Thrombosis Research Society, 2016-
American Society of Hematology, 2016-
American Society of Pediatric Hematology/Oncology, 2016-
International Society on Thrombosis and Haemostasis, 2017-
Professional Awards
Phi Beta Kappa, Emory University College of Arts and Sciences, 2007
Alpha Omega Alpha Medical Honor Society, Emory School of Medicine, 2011
Abstract Achievement Award, American Society of Hematology, 2011
Abstract Achievement Award, American Society of Hematology, 2017
Publication Highlights
Doshi BS, Rana J, Castaman G, Shaheen MA, Kaczmarek R, Butterfield JS, Meeks SL, Leissinger C, Biswas M, Arruda VR. B cell-activating factor modulates the factor VIII immune response in hemophilia A. J Clin Invest. 2021 Apr; 131(8): e142906. PubMed PMID: 33651716
Doshi BS, Raffini LJ, George LA. Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors. J Thromb Haemost. 2020 Apr; In Press, 2020
Doshi BS, Rogers RS, Whitworth HB, Stabnick EA, Britton J, Butler RB, Obstfeld AE, Witmer CM. Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients. J Thromb Haemost. 2019 Nov; 17(11): 1838-1847. Pub Med PMID: 31350816
Meeks SL, Cox CL, Healey JF, Parker ET, Doshi BS, Gangadharan B, Barrow RT, Lollar P. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood. 2012 Sep; 120(12): 2512-20. PubMed PMID: 22855607
Doshi BS, Gangadharan B, Doering CB, Meeks SL. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. PLoS One. 2012 Jan; 7(10): e48172. PubMed PMID: 23144741